Peptide Knowledge Base · Immune

ARA-290 (Cibinetide): what it is, what the evidence says, and its real status

An EPO-derived peptide engineered to keep the tissue-protective effect without raising red blood cells. Real but early human trials in neuropathy.

Can you actually get it?

Plain-English verdict: No availability record.

Regulatory status: No regulatory record.

How does ARA-290 (Cibinetide) work?

A peptide mimicking the tissue-protective receptor activity of erythropoietin without stimulating red-blood-cell production.

What it does — and what it does not do

What it does: Studied for small-fiber neuropathic pain and inflammatory conditions in early human trials.

What it does not do: It is not approved or available, and the trial evidence is early.

How honest is the evidence?

Evidence grade C — Mixed / early human evidence.

some human trials (sarcoidosis neuropathy); not approved

A grade measures how much human evidence exists, not whether a molecule is good, safe, or worth your interest. Read our grading methodology for what each grade means.

What we still don't know: Efficacy and long-term safety are not established beyond early trials.

WADA status: Banned (S2, EPO class caution).

How it is taken

What the literature reports: subcutaneous. Educational only, no dose figures.

Who should not take it

Investigational; EPO-class caution; clinician-gated. Not characterized for general use.

Sources

Cibinetide (ARA-290) neuropathy trial literature (early-clinical)

Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker for status.

Join the founding list →

Embed this card on your site · free, CC BY 4.0, no key.

Last reviewed Jun 18, 2026 · Peptós.LIFE · Not medical advice.